marimastat has been researched along with Lung Neoplasms in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, W; Xiao, Q; Yin, L; Yuan, Y; Zhu, X | 1 |
| Bezjak, A; Debruyne, C; Giaccone, G; Hirsh, V; Krzakowski, M; Lamont, A; Martins, H; Rubin, S; Sadura, A; Seymour, L; Shepherd, FA; Smylie, M; Zee, B | 1 |
| King, J; Morris, DL; North, H | 1 |
| Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG | 1 |
| Chiodo, TA; Dickson, R; Hawkins, MJ; Johnson, M; Marshall, J; Ness, E; Rasmussen, HS; Sale, M; Steen, V; Torri, J; Wojtowicz-Praga, S | 1 |
| Bout, JC; Soncin, F; Vandenbunder, B | 1 |
| Brown, PD | 1 |
| Fukuoka, M | 1 |
1 review(s) available for marimastat and Lung Neoplasms
| Article | Year |
|---|---|
[Progress in diagnosis and treatment of lung cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Endothelial Growth Factors; Enzyme Inhibitors; Gefitinib; Genetic Therapy; Humans; Hydroxamic Acids; Lung Neoplasms; Lymphokines; Mass Screening; Metalloendopeptidases; Quinazolines; Receptor Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
4 trial(s) available for marimastat and Lung Neoplasms
| Article | Year |
|---|---|
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Orga
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Canada; Carcinoma, Small Cell; Double-Blind Method; Enzyme Inhibitors; Europe; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Metalloendopeptidases; Middle Aged; Patient Compliance; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome | 2002 |
Effect of marimastat on serum tumour markers in patients with colorectal cancer.
Topics: Adult; Aged; Carcinoembryonic Antigen; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2000 |
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Nausea; Paclitaxel; Treatment Outcome | 2005 |
Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
Topics: Administration, Oral; Aged; Arthritis; Collagenases; Enzyme Inhibitors; Female; Gelatinases; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metalloendopeptidases; Middle Aged; Treatment Outcome | 1998 |
3 other study(ies) available for marimastat and Lung Neoplasms
| Article | Year |
|---|---|
A drug-delivering-drug strategy for combined treatment of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caseins; Cell Proliferation; Drug Combinations; Drug Delivery Systems; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinases; Mice; Nanoparticles; Paclitaxel; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
[Therapeutic prospects of angiogenesis inhibitors in cancerology].
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Collagen; Endostatins; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinase Inhibitors; Mice; Neoplasms; Neoplasms, Experimental; Neovascularization, Pathologic; Peptide Fragments; Plasminogen; Protease Inhibitors; Randomized Controlled Trials as Topic | 1999 |
Ongoing trials with matrix metalloproteinase inhibitors.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinase Inhibitors; Organic Chemicals; Phenylbutyrates | 2000 |